Breast Cancer Research and Treatment

, Volume 4, Issue 3, pp 221–225 | Cite as

Thymidine kinase as a predictor of response to chemotherapy in advanced breast cancer

  • Hui-Jian Zhang
  • B. J. Kennedy
  • David T. Kiang


Cytosols from breast cancers were measured for estrogen receptor (ER) and thymidine kinase (TK) activity. There was no correlation between ER and TK in 137 primary breast cancers studied. The results of TK from 57 metastatic breast cancers were correlated with the response or failure to subsequent hormonal therapy or chemotherapy. TK did not predict the responses to hormonal therapy in 12 patients. Of the 45 patients treated with chemotherapies, 13 of 15 tumors with TK over 80 pmol/mg/min responded (86%), while only 4 of the 30 tumors (13%) with TK below 80 pmol/mg/min responded (p<0.001). TK appears to be useful in predicting the responses to chemotherapy.


breast cancer chemotherapy response prediction thymidine kinase 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    McGuire WL, Carbone PP, Vollmer EPC (eds): Estrogen Receptors in Human Breast Cancer. Raven Press, New York, 1975Google Scholar
  2. 2.
    Salmon SE (ed): Cloning of Human Tumor Stem Cells. Alan R Liss, New York, 1980Google Scholar
  3. 3.
    Kit S: Thymidine kinase, DNA synthesis and cancer. Mol Cell Biochem 11:161–182, 1976PubMedGoogle Scholar
  4. 4.
    Bronzert DA, Monaco ME, Pinkus L, Aitken S, Lippman ME: Purification and properties of estrogen-responsive cytoplasmic thymidine kinase from human breast cancer. Cancer Res 41:604–610, 1981Google Scholar
  5. 5.
    Valeriote F, van Putten L: Proliferation-dependent cytotoxicity of anticancer agents (Review). Cancer Res 35:2619–2630, 1975PubMedGoogle Scholar
  6. 6.
    Rajewsky MF: Proliferative parameters relevant to cancer therapy. Recent Results Cancer Res 2:156–171, 1975Google Scholar
  7. 7.
    Breitmen TR: The feedback inhibition of thymidine kinase. Biochim Biophys Acta 67:153–166, 1963PubMedGoogle Scholar
  8. 8.
    Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurement with the Folin-phenol reagent. J Biol Chem 193:265–275, 1951PubMedGoogle Scholar
  9. 9.
    McGuire WL, DeLaGarza M, Chamness GC: Evaluation of estrogen receptor assays in human breast cancer tissue. Cancer Res 37:637–639, 1977PubMedGoogle Scholar
  10. 10.
    Hayward JL, Carbone PP, Heuson J-C, Kumaoka S, Segaloff A, Rubens R: Assessment of response to therapy in advanced breast cancer. A project on the Programme of Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland. Cancer 39:1289–1294, 1977PubMedGoogle Scholar
  11. 11.
    Lippman ME, Allegra JC, Thompson EB: The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer. N Engl J Med 298:1223–1228, 1978PubMedGoogle Scholar
  12. 12.
    Kiang DT, Frenning DH, Goldman AI, Ascensao VF, Kennedy BJ: Estrogen receptors and responses to chemotherapy and hormonal therapy in advanced breast cancer. N Engl J Med 299:1330–1334, 1978PubMedGoogle Scholar
  13. 13.
    Special report: Steroid receptors in breast cancer. N Engl J Med 301:1011–1012, 1979Google Scholar
  14. 14.
    Zhang H-J, Snover D, Kennedy BJ, Kiang DT: Correlation of thymidine kinase activity, histology and steroid receptors in primary breast cancer (Abstract C-29). Proc Am Soc Clin Oncol 1:8, 1982Google Scholar
  15. 15.
    Kiang DT, King M, Zhang H-J, Kennedy BJ, Wang N: Cyclic biological expression in mouse mammary tumors. Science 216:68–70, 1982PubMedGoogle Scholar
  16. 16.
    Selby P, Buick RN, Tannock I: A critical appraisal of the ‘human tumor stem cell assay’. N Engl J Med 308:129–134, 1983PubMedGoogle Scholar
  17. 17.
    Von Hoff DD: Send this patient's tumor for culture and sensitivity (editorial). N Engl J Med 308:154–155, 1983PubMedGoogle Scholar

Copyright information

© Martinus Nijhoff Publishers 1984

Authors and Affiliations

  • Hui-Jian Zhang
    • 1
  • B. J. Kennedy
    • 1
  • David T. Kiang
    • 1
  1. 1.Section of Medical Oncology, Department of MedicineUniversity of Minnesota School of MedicineMinneapolisUSA

Personalised recommendations